| Capecitabine and oxaliplatin for advanced esophagogastric cancer D Cunningham, N Starling, S Rao, T Iveson, M Nicolson, F Coxon, ... New England Journal of Medicine 358 (1), 36-46, 2008 | 2830 | 2008 |
| Patient-derived organoids model treatment response of metastatic gastrointestinal cancers G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ... Science 359 (6378), 920-926, 2018 | 1743 | 2018 |
| Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial JS Waters, A Norman, D Cunningham, JH Scarffe, A Webb, P Harper, ... British journal of cancer 80 (1), 269-272, 1999 | 416 | 1999 |
| Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer S Rao, D Cunningham, A De Gramont, W Scheithauer, M Smakal, ... Journal of Clinical Oncology 22 (19), 3950-3957, 2004 | 290 | 2004 |
| Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL … D Cunningham, S Rao, N Starling, T Iveson, M Nicolson, F Coxon, ... Journal of Clinical Oncology 24 (18_suppl), LBA4017-LBA4017, 2006 | 265 | 2006 |
| Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients … K Sumpter, C Harper-Wynne, D Cunningham, S Rao, N Tebbutt, ... British journal of cancer 92 (11), 1976-1983, 2005 | 248 | 2005 |
| Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer A Woolston, K Khan, G Spain, LJ Barber, B Griffiths, R Gonzalez-Exposito, ... Cancer cell 36 (1), 35-50. e9, 2019 | 238 | 2019 |
| Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial KH Khan, D Cunningham, B Werner, G Vlachogiannis, I Spiteri, T Heide, ... Cancer discovery 8 (10), 1270-1285, 2018 | 238 | 2018 |
| Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey SY Moorcraft, C Marriott, C Peckitt, D Cunningham, I Chau, N Starling, ... Trials 17, 1-12, 2016 | 232 | 2016 |
| Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK … N Starling, S Rao, D Cunningham, T Iveson, M Nicolson, F Coxon, ... Journal of clinical oncology 27 (23), 3786-3793, 2009 | 227 | 2009 |
| Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ S Rao, MG Guren, K Khan, G Brown, AG Renehan, SE Steigen, ... Annals of Oncology 32 (9), 1087-1100, 2021 | 177 | 2021 |
| Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer S Rao, D Cunningham, RE Hawkins, ME Hill, D Smith, F Daniel, PJ Ross, ... British journal of cancer 92 (9), 1650-1654, 2005 | 174 | 2005 |
| Upper gastrointestinal clinical studies group of the National Cancer Research Institute of the United Kingdom capecitabine and oxaliplatin for advanced esophagogastric cancer D Cunningham, N Starling, S Rao, T Iveson, M Nicolson, F Coxon, ... N Engl J Med 358 (1), 36-46, 2008 | 161 | 2008 |
| Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative J Bogaerts, MR Sydes, N Keat, A McConnell, A Benson, A Ho, A Roth, ... European journal of cancer 51 (3), 271-281, 2015 | 150 | 2015 |
| Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal … PS Hall, D Swinson, DA Cairns, JS Waters, R Petty, C Allmark, S Ruddock, ... JAMA oncology 7 (6), 869-877, 2021 | 143 | 2021 |
| Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced … S Rao, N Starling, D Cunningham, K Sumpter, D Gilligan, T Ruhstaller, ... Annals of Oncology 21 (11), 2213-2219, 2010 | 143 | 2010 |
| International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct S Rao, F Sclafani, C Eng, RA Adams, MG Guren, D Sebag-Montefiore, ... Journal of Clinical Oncology 38 (22), 2510-2518, 2020 | 125 | 2020 |
| Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment A Newey, B Griffiths, J Michaux, HS Pak, BJ Stevenson, A Woolston, ... Journal for immunotherapy of cancer 7, 1-15, 2019 | 123 | 2019 |
| Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial H Kennecke, S Berry, R Wong, C Zhou, K Tankel, J Easaw, S Rao, J Post, ... European Journal of Cancer 48 (1), 37-45, 2012 | 99 | 2012 |
| A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify … NJ Battersby, M Dattani, S Rao, D Cunningham, D Tait, R Adams, ... Trials 18, 1-14, 2017 | 95 | 2017 |
